Postoperative Narcotic Use After Laparoscopic Gynecologic Surgery

• Status: Withdrawn
• Trial end date: 2020-07-30
• Target enrollment: 0
• Participant gender: Female

Summary

This will be a prospective, randomized, double blinded placebo-controlled study at Erlanger hospital. Eligible patients who provide consent will be randomized into one of two arms receiving continuous intra-peritoneal local anesthetic with 0.2% Ropivacaine or saline.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Camille Ladanyi MD; University of Tennessee, Chattanooga
• Treatments: Narcotics; Ropivacaine

Criteria

Inclusion Criteria:

1. All patients undergoing laparoscopic gynecologic surgery with either the traditional "straight stick" or robotic assisted techniques will be considered for eligibility. Eligible patients will include those with pelvic pain and endometriosis as well as those who present for pelvic floor reconstruction. Surgical procedures performed will include excision of endometriosis, lysis of adhesions, hysterectomy, bilateral or unilateral salpingo-oophorectomy, cystectomy, and pelvic reconstruction.

2. Patients who are 18 years or older

3. Patients who provide written surgical consent

4. Patients who are capable and willing to follow up with surveys and complete pain and pill diaries

Exclusion Criteria:

1. Patients who are unable or willing to provide consent and complete the follow up surveys and dairies

2. Patients who are allergic to Ropivacaine

3. Patients whose minimally invasive procedures were converted to laparotomies